Two Sigma Investments LP Makes New $159,000 Investment in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Two Sigma Investments LP acquired a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,314 shares of the company’s stock, valued at approximately $159,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AlphaQuest LLC acquired a new stake in ClearPoint Neuro during the 4th quarter worth approximately $80,000. Tower Research Capital LLC TRC acquired a new stake in shares of ClearPoint Neuro during the fourth quarter worth $93,000. State of Wyoming bought a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $145,000. Occudo Quantitative Strategies LP bought a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $155,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of ClearPoint Neuro in the fourth quarter valued at about $204,000. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Stock Performance

NASDAQ:CLPT opened at $12.08 on Friday. The company has a market cap of $338.11 million, a price-to-earnings ratio of -17.51 and a beta of 0.93. ClearPoint Neuro, Inc. has a fifty-two week low of $5.11 and a fifty-two week high of $19.22. The stock has a fifty day moving average price of $12.79 and a 200-day moving average price of $14.31.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). The company had revenue of $8.49 million during the quarter, compared to analyst estimates of $8.21 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. Research analysts predict that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

Insider Transactions at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 21,247 shares of ClearPoint Neuro stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $13.29, for a total value of $282,372.63. Following the transaction, the chief executive officer now directly owns 243,522 shares of the company’s stock, valued at $3,236,407.38. This trade represents a 8.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Timothy T. Richards sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $13.28, for a total transaction of $132,800.00. Following the transaction, the director now owns 77,381 shares of the company’s stock, valued at approximately $1,027,619.68. This represents a 11.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.97% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Wall Street Zen cut shares of ClearPoint Neuro from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Stifel Nicolaus raised their target price on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.